Targeted radiation tested for prostate cancer patients with dangerous blood counts
NCT ID NCT07025512
Summary
This study is testing a targeted radiation drug called 177Lu-PSMA-617 in men with advanced prostate cancer that has spread to the bone marrow and caused low blood cell counts. The main goal is to see if the treatment is safe and effective for this specific group of patients who often have fewer treatment options. Researchers will enroll about 40 participants to closely monitor their health and the drug's impact on their cancer and blood counts.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.